Health Canada — Medical Devices · Canada · 2016-01-28 · Type II
🏛Compiled from an official source — the facts on this page are reproduced from the issuing authority’s own published notice, which is linked above. No AI-generated text appears on this page. How we use AI →
Archived by the issuing authority — kept for reference
Reported risk: Analysis of patient samples received in complaint investigations showed that several samples caused unspecific signals up to 22 U/mL. The unspecific signals are neither caused by anti-Sm antibodies nor by anti-streptavidin antibodies but are due to other unspecific signals with an as yet unknown cause.
Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.
ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.